Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
  • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
  • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
  • A61K51/04—Organic compounds
  • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
  • A61K51/0476—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group complexes from monodendate ligands, e.g. sestamibi
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
  • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
  • A61K51/04—Organic compounds
  • A61K51/0489—Phosphates or phosphonates, e.g. bone-seeking phosphonates
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/04—Centrally acting analgesics, e.g. opioids
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P35/00—Antineoplastic agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P35/00—Antineoplastic agents
  • A61P35/02—Antineoplastic agents specific for leukemia
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P35/00—Antineoplastic agents
  • A61P35/04—Antineoplastic agents specific for metastasis

Definitions

• the present invention relates to a method for the improved treatment of a cancerous disease in a patient and/or for the palliation of pain associated with cancer diseases, comprising the administration of a tubulin interacting compound in combination with a bone-localising radiopharmaceutical to said patient in an effective amount that will not cause any substantial ablation of the bone marrow of said patent.
• the cancerous disease is selected from the group of cancer diseases, comprising multiple myeloma, leukaemia, lymphoma, breast cancer, prostate cancer, gynecologic cancer, gastric cancer ovarian cancer, lung cancer and/or renal cell carcinoma.
• the invention furthermore relates to the use of a bone-localising radiopharmaceutical for the preparation of a pharmaceutical composition for the treatment of cancer diseases and/or for the palliation of pain associated with cancer diseases, comprising the administration of the bone-localising agent in combination with a tubulin interacting compound to the patient in an effective amount that will not cause a any substantial ablation of the bone marrow of said patient.
• the invention still further relates to the use of a tubulin interacting compound for the preparation of a pharmaceutical composition for the treatment of cancer diseases and/or for the palliation of pain associated with cancer diseases, comprising the administration of the tubulin interacting compound in combination with a bone-localising radiopharmaceutical to the patient in an effective amount that will not cause any substantial ablation of the bone ma ⁇ ow of said patient.
• the bone-localising radiopharmaceutical is samarium Sm 153 lexidronam and the tubulin interacting compound is docetaxel.
• Prostate cancer is the most common noncutaneous malignancy in men and is the second leading cause of cancer death in males in the United States. There will be an estimated 189,000 new cases diagnosed and 30,200 deaths due to prostate cancer in 2002 (Ahmedin 2002). In patients with advanced prostate cancer, the primary site of metastasis is bone, although soft-tissue metastases can also occur. Because of the hormone-responsive nature of prostate cancer, the initial management of patients with advanced disease usually involves androgen deprivation. While androgen deprivation leads to stabilisation or regression of disease in more than 80%) of patients, the median duration of response is less than 2 years due to the eventual overgrowth of hormone-refractory cells. Following development of hormone- refractory prostate cancer (HRPC), median survival is approximately 1 year (Kish 2001). Treatment options for patients with HRPC are limited and have been focused on palliation, highlighting the need for more effective therapeutic strategies.
• HRPC hormone- refractory prostate cancer
• estramustine-based regimens have recently demonstrated the ability to reduce PSA levels and induce measurable disease responses in patients with HRPC (Hudes 1997a, 1997b, 1999, Seidman 1992, Petrylak 1999a, 1999b, Kreis 1999a, 1999b, Savarese 2001).
• the do- cetaxel/estramustine combination has been viewed as the most attractive of these regimens because of its clinical efficacy, convenient administration schedule, and improved toxicity profile.
• the regimen has demonstrated evidence of synergistic antitumor activity against HRPC in both preclinical and clinical studies (Petrylak 1999a, Petrylak 1999b, Kreis 1999a, Kreis 1999b, Savarese 1999).
• Docetaxel inhibits tumour growth through induction of microtubule stabilisation by binding to B-tubulin and promotion of bcl-2 inactivation, thereby sensitising malignant cells to apoptotic stimuli (Ringel 1991, Haldar 1997, Friedland 1999).
• Estramustine an estradiol-nitrogen mustard conjugate, also exerts antitumor effects by binding with B-tubulin and microtubule- associated proteins (Laing 1997).
• Samarium Sm 153 lexidronam is a radiopharmaceutical that has an affinity for skeletal tissue and concentrates in areas of bone turnover secondary to invasion by tumour (Goeckeler 1987). It has been approved by the FDA for the relief of pain in patients with os- teoblastic metastatic bone lesions at a dose of 1.0 mCi/kg.
• the radioisotope with a half-life of 46.3 hours, emits a 103 keV gamma ray for external imaging and a number of beta particles (average energy 233 keV) for localised radiotherapy.
• the range of emission of samarium Sm 153 lexidronam is only 1.7 mm in bone, limiting the exposure of bone ma ⁇ ow and other adjacent tissues to radiation.
• the degree of skeletal uptake of samarium Sm 153 lexidronam correlates with the extent of osteoblastic bone disease.
• the ratio of uptake of samarium Sm 153 lexidronam by skeletal lesions relative to normal bone is approximately 5:1.
• There is no significant uptake by nonosseous tissue (Eary 1993). Clearance of samarium Sm 153 lexidronam is exclusively renal, with the majority of excretion occurring during the first 8 hours after administration, and complete excretion by 12 hours (Serafini 2001).
• the major toxicity of samarium Sm 153 lexidronam is haematologic.
• samarium Sm 153 lexidronam The major toxicity of samarium Sm 153 lexidronam is haematologic.
• Grade 3/4 haematologic toxicity was seen in ⁇ 10% of patients, and generally occurred in patients who had recently undergone external beam radiation or chemotherapy, had low blood counts on study entry, or had proven or probable bone marrow involvement with metastatic prostate cancer (Serafini 2001).
• a number of chemotherapy agents have demonstrated radiosensitising properties, including docetaxel and estramustine (Pradier 2001, Koukourakis 1998a, 1998b, Koukourakis 1999, Ekiov 1994, Ryu 1994, Edgren 2000, Kim 1994), making them attractive candidates for use in combination with radionuclides.
• the majority of radionuclide combination experience is with strontium 89 chloride.
• Estramustine has been evaluated in combination with strontium 89 chloride in several trials because of its radiosensitising properties and lack of myelosuppres- sion.
• the combination has been shown to be well tolerated, with no Grade 3/4 neutropenia, 6% Grade 3 thrombocytopenia, and 3% Grade 3 anaemia.
• PSA response rates were in the order of 31 %, with a median duration of 7 months (Dahut 1998). Similar results have been observed when strontium 89 chloride was combined with carboplatin (Sciuto 1998).
• WO 00/76556 discloses the use of 153 Sm-EDTMP together with bioactive agents, such as an- tineoplastic chemotherapeutic agents for the partial or complete suppression of bone ma ⁇ ow and the treatment of bone marrow diseases, such as cancer.
• bioactive agents such as an- tineoplastic chemotherapeutic agents for the partial or complete suppression of bone ma ⁇ ow and the treatment of bone marrow diseases, such as cancer.
• One example would be paclitaxel.
• the chemotherapeutic agent can be applied in conjunction with the radiotherapeutic.
• the publication is directed to replacing TBI (total bone irradiation) with the administration of, e.g. 166 Ho-DOTMP in a bone-associated pathology in a dosage to deliver 20 to 60 Gy to the patient, and the administration of the chemotherapeutic after the complex.
• the document is therefore related to the suppression of the bone ma ⁇ ow in order to provide a predominantly background" for bone marrow transplantation.
• the publication is directed to the most effective killing of the diseased bone marrow of the patient.
• Nothing is disclosed with respect to pain relief as an indication. Arteaga de Murphy C, et al.
• This first object of the present invention is solved by a method for the improved treatment of a cancerous disease in a patient and/or for the palliation of pain associated with cancer diseases, comprising the administration of a tubulin interacting compound in combination with a bone-localising radiopharmaceutical to said patient in an effective amount that will not cause any substantial ablation of the bone ma ⁇ ow of said patent.
• a method for the improved treatment of a cancerous disease in a patient and/or for the palliation of pain associated with cancer diseases comprising the administration of a tubulin interacting compound in combination with a bone-localising radiopharmaceutical to said patient in an effective amount that will not cause any substantial ablation of the bone ma ⁇ ow of said patent.
• the term "substantial” is generally to be understood by reference to the art- recognised definitions.
• substantially is meant an ablation, wherein the damage to the bone ma ⁇ ow as caused by the radiopharmaceutical, will cause an ablation of the hematologically active cells (including the stem cells) inside the bone ma ⁇ ow to such an extent that the patient will require a bone- arrow supportive treatment in order to maintain/retain a sufficient function of the bone marrow.
• a “substantial” ablation will be a complete ablation of the bone ma ⁇ ow of the patient.
• Another aspect of the present invention provides for the use of a bone-localising radiopharmaceutical for the preparation of a pharmaceutical composition for the treatment of cancer diseases and/or for the palliation of pain associated with cancer diseases, comprising the administration of the bone-localising agent in combination with a tubulin interacting compound to the patient in an effective amount that will not cause a any substantial ablation of the bone marrow of said patient.
• the invention provides for the use of a tubulin interacting compound for the preparation of a pharmaceutical composition for the treatment of cancer diseases and/or for the palliation of pain associated with cancer diseases, comprising the administration of the tubulin interacting compound in combination with a bone-localising radiopharmaceutical to the patient in an effective amount that will not cause any substantial ablation of the bone ma ⁇ ow of said patient.
• said cancerous disease is selected from the group of cancerous diseases, comprising multiple myeloma, leukaemia, lymphoma, breast cancer, ovarian cancer, prostate cancer, lung cancer, and renal cell carcinoma.
• said cancerous disease can be a cancer with bone metastasis, such as metastatic breast cancer or metastatic prostate cancer.
• HRPC hormone-refractory prostate cancer
• said bone-localising radiopharmaceutical is selected from the group consisting of the radionuclides 177 Lu, 175 Yb, 186 Re, 188 Re, 90 Y, 1 17 mSn, 153 Sm, 166 Ho or 159 Gd that are complexed with a bone-localising chelating agent selected from the group consisting of aminophosphonic acids, in particular samarium Sm 153 lexidronam, and 89 Sr-chloride.
• Prefe ⁇ ed are aminophosphonic acids which are se- lected from the group consisting of EDTMP, DOTMP, DTPMP, HEEDTMP, NTMP, HEDP, HMDP, MDP, and TTHMP, and combinations thereof.
• said bone-localising radiopharmaceutical is administered at a dose of between about 0.005 to 5.0 mCi/kg, and preferably administered at a dose of 1.0 mCi/kg.
• said tubulin interacting compound is administered before or after the administration of said bone-localising radiopharmaceutical.
• the amount that is given is effective for bone pain relief in said patient.
• said tubulin interacting compound is administered at a dose of between 20 to 100 mg/m /week, and preferably administered at a dose of between 30 to 70 mg/m /week.
• Most prefe ⁇ ed are a weekly administration of Taxol of approx.
• tubulin interacting compound is a chemotherapeutic agent selected from the group comprising docetaxel, estramustine, doxorubicin, paclitaxel, tamoxifen, vinblastine, vinorelbine, vindesine, vincristine cyclophosphamide, and the like.
• anti-microtubule agents are as follows: Vinca alkaloids (vincristine, vinblastine, vindesine, vinorelbine), Taxanes (paclitaxel, docetaxel), estramustine phosphate, and compounds like, for example, epothilone A and B.
• tubulin interacting compounds can be found in the respective literature, for example, in Jiang JD, et al. "Double blockade of cell cycle at g(l)-s transition and m phase by 3-iodoacetamido benzoyl ethyl ester, a new type of tubulin ligand.” Cancer Res. 2002 Nov l ;62(21):6080-8.; Bocca C, et al. "Cytoskeleton-interacting activity of geiparvarin, diethylstilbestrol and conjugates.” Chem Biol Interact. 2001 Sep 28;137(3):285-305.; Botta B, et al.
• the administration of said bone-localising radiopharmaceutical is performed in a time period ranging from about 1 to 30 days, and preferably 1 to 7 days, before and/or after the administration of said tubulin interacting compound.
• Prefe ⁇ ed is a method according to the present invention, wherein the bone-localising radiopharmaceutical is administered in at least 8 week-intervals during the course of a weekly administration of said tubulin interacting compound.
• the bone-localising radiopharmaceutical is administered in at least 8 week-intervals during the course of an administration every three weeks of said tubulin interacting compound.
• prefe ⁇ ed is a method according to the present invention, wherein said bone-localising radiopharmaceutical is administered on day 2 of said treatment cycles, and said tubulin interacting compound is administered on day 1 of weeks 1-3, 5-7, 9-11, and 13-15 of said treatment cycles, more prefe ⁇ ed is a method, wherein said bone-localising radiopharmaceutical is 153Sm-EDTMP being administered at a dose of lmCi/kg, and said tubulin interacting compound is docetaxel being administered at a dose of 30mg/m 2 /week.
• estramustine phosphate sodium is administered during weeks 1-3, 5-7, 9-11, and 13- 15 of said treatment cycles.
• estramustine phosphate sodium Emcyt®
• said estramustine phosphate sodium will be administered on Days 1-3 of Weeks 1-3 and 5-7 of each 8- week cycle and will be given at a dose of between approx. 100 to 400 mg, preferably approx. 280 mg twice a day orally (p.o.).
• said estramustine phosphate sodium is administered on days 1 to 3 of weeks 1-3, 5-7, 9-11, and 13-15 of said treatment cycles.
• said estramustine phosphate sodium is administered at a dose of 280 mg twice a day.
• the dose can be varied, depending from the individually tolerated dose and the amount that would be needed in order to enhance the treatment effect.
• 1 to 8 of said treatment cycles are performed.
• the treatment regimen can also been summarised in table 1 as follows.
• Table 1 First exemplary treatment regimen according to the present invention
• Tubulin interact comp. + + + - + + + + . estramustine (opt.) + + + + . + + . week 9 10 11 12 13 14 15 16 radiopharmaceutical - - - - - - - - -
• Tubulin interact, comp. + + + - + + + + . estramustine (opt.) + + + + . + + + .
• Prefe ⁇ ed is a method according to the present invention, wherein said bone-localising radiopharmaceutical is administered on day 2 of said treatment cycles, and said tubulin interacting compound is administered on day 1 of weeks 1-3, and 5-7 of said treatment cycles.
• said bone-localising radiopharmaceutical is 153Sm-EDTMP being administered at a dose of approx. ImCi/kg
• said tubulin interacting compound is docetaxel being administered at a dose of administered at a dose of between 30 to 70 mg/m /week.
• estramustine phosphate sodium is administered during weeks 1-3, and 5-7 of said treatment cycles. Even more preferably, said estramustine phosphate sodium is administered on days 1 to 3 of weeks 1-3, and 5-7 of said treatment cycles. Ideally, said estramustine phosphate sodium is administered at a dose of 280 mg twice a day.
• Table 2 Second exemplary treatment regimen according to the present invention Week 1 2 3 4 5 6 7 8 Radiopharmaceutical +
• Tubulin interact.
• the administration is intravenous (i.v.), orally (p.o.), and/or subcutaneously. Further, the administration can be in a bolus dose or in several doses, independently from the different embodiments of the method according to the present invention.
• the different treatment regimen can be combined, e.g. first performing the second ("short") exemplary treatment regimen according to the present invention and, thereafter, performing the first ("long”) exemplary treatment regimen according to the present invention, or vice versa.
• Another aspect of the present invention is related to a method for the treatment of a bone- associated cancer in a patient and/or for the palliation of pain associated with a bone- associated cancer, comprising the administration of a tubulin interacting compound in combination with a bone-localising radiopharmaceutical to said patient in an effective amount that will not cause any substantial ablation of the bone ma ⁇ ow of said patient.
• said bone-associated cancer is selected from the group of metastatic cancerous diseases, comprising multiple myeloma, leukaemia, lymphoma, breast cancer, ovarian cancer, prostate cancer, lung cancer, and renal cell carcinoma.
• Most prefe ⁇ ed is a method according to the present invention, wherein said cancerous disease is hormone-refractory prostate cancer (HRPC).
• HRPC hormone-refractory prostate cancer
• said tubulin interacting compound is administered before or after the administration of said bone-localising radiopharmaceutical, preferably in an amount that is effective for bone pain relief in said patient.
• said bone-localising radiopharmaceutical is selected from the group consisting of the radionu- clides 177 Lu, 175 Yb, , 86 Re, 188 Re, 90 Y, 117 mSn, 153 Sm, 166 Ho or 159 Gd that are complexed with a bone-localising chelating agent selected from the group consisting of aminophosphonic acids, in particular samarium Sm 153 lexidronam, and Sr-chloride.
• aminophosphonic acids which are selected from the group consisting of EDTMP, DOTMP, DTPMP, HEEDTMP, NTMP, HEDP, HMDP, MDP, and TTHMP, and combinations thereof.
• said bone-localising radiopharmaceutical is administered at a dose of between about 0.005 to 5.0 mCi/kg, and preferably administered at a dose of 1.0 mCi/kg.
• said tubulin interacting compound is administered at a dose of between 20 to 100 mg/m /week, further preferably administered at a dose of between 30 to 70 mg/m /week, and most prefe ⁇ ed administered at a dose of approximately 30 mg/m /week.
• said tubulin interacting compound is a chemotherapetic agent selected from the group comprising docetaxel, estramustine, doxorubicin, paclitaxel, tamoxifen, vinblastine, vinorelbine, vindesine, vincristine cyclophosphamide, and the like.
• chemotherapetic agent selected from the group comprising docetaxel, estramustine, doxorubicin, paclitaxel, tamoxifen, vinblastine, vinorelbine, vindesine, vincristine cyclophosphamide, and the like.
• Other suitable compounds are indicated above.
• Another important aspect of the method for treatment of a bone-associated cancer according to the present invention relates to the seekingtiming" (i.e. treatment regimen) of the dosages of the radiotherapeutic and/or the tubulin interacting compound to be applied.
• the treatment schedule can be as above with minor amendments that are based on the different s of bone-associated cancer that might be involved and the individual patient parameters of the patient(s) to be treated. These amendments can be easily determined by the skilled person, such as the attending physician.
• kits of parts for the treatment of a cancer disease and/or for the palliation of pain associated with cancer diseases comprising the following components: a) a pharmaceutically effective amount of a bone-localising radiopharmaceutical, b) a pharmaceutically effective amount of a tubulin interacting compound, and c) optionally, suitable pharmaceutically acceptable buffers and/or diluents, wherein the amount of the bone-localising radiopharmaceutical comprises an effective amount of said bone-localising radiopharmaceutical that will not cause any substantial ablation of the bone ma ⁇ ow when applied to a patient.
• kits according to the present invention wherein said bone-localising radiophar- maceutical is selected from the group consisting of the radionuclides Lu, Yb, Re, 188 Re, 90 Y, 117 mSn, 153 Sm, 166 Ho or 159 Gd that are complexed with a bone-localising chelating agent selected from the group consisting of aminophosphonic acids, in particular samarium on
• aminophosphonic acids are selected from the group consisting of EDTMP, DOTMP, DTPMP, HEEDTMP, NTMP, HEDP, HMDP, MDP, and TTHMP, and combinations thereof.
• said bone- localising radiopharmaceutical is suitable for the administration at a dose of between about 0.005 to 5.0 mCi/kg, preferably at a dose of 1.0 mCi/kg
• said tubulin interacting compound is suitable for the administration at a dose of between 20 to 100 mg/m 2 /week, further preferably administered at a dose of between 30 to 70 mg/m 2 /week, and most prefe ⁇ ed administered at a dose of approximately 30 mg/m 2 /week.
• the tubulin interacting compound is suitable for administration before or after the administration of the bone-localising radiopharmaceutical, preferably suitable for administration at a dose of between 20 to 100 mg/m 2 /week, further preferably administered at a dose of between 30 to 70 mg/m /week, and most prefe ⁇ ed administered at a dose of approximately 30 mg/m /week.
• the tubulin interacting compound is a directly and/or indirectly tubulin-interacting chemotherapetic agent selected from the group comprising docetaxel, doxorubicin, tamoxifen, vinblastine, vinorelbine, vindesine, vincristine cyclophosphamide, and the like.
• Other suitable tubulin interacting compounds are as above.
• other chemotherapeutical agents such as, for example, paclitaxel and/or estramustine can be administered during the course of the therapy as well.
• said bone-localising radiopharmaceutical is suitable for administration in a time period ranging from about 1 to 30 days, and preferably 1 to 7 days, before and/or after the administration of said tubulin interacting compound. Even more preferably, said bone-localising radiopharmaceutical is suitable for administration in at least 8 week-intervals during the course of a weekly administration of said tubulin interacting compound. Even more preferably, said bone-localising radiopharmaceutical is suitable for administration in at least 8 week-intervals during the course of an administration every three weeks of said tubulin interacting compound.
• kits can either be ready-to-use or form kits that are used to prepare the active agents immediately before use, for example, by mixing different ingredients.
• a kit is described for tumour and metastasis scintigraphy in Chauhan UP, et al. (in: "Evaluation of a DMSA kit for instant preparation of 99mTc(V)- DMSA for tumour and metastasis scintigraphy.” Int J Rad Appl Instrum B 1992 Nov;19(8):825-30) for instantly preparing 99mTc(V)-DMSA.
• the kit can be produced by a robot, as described, for example, in Luurtsema G, et al ("An automated synthesis module for preparation of L-3-[123I]iodo-alpha-methyl tyrosine.” Appl Radiat Isot 2001 Dec;55(6):783-8).
• the present invention in one aspect features the use of a bone-localising radiopharmaceutical for the preparation of a pharmaceutical composition for the treatment of cancer diseases and/or for the palliation of pain associated with cancer diseases, comprising the administration of the bone-localising radiopharmaceutical agent in combination with a tubulin interacting compound to the patient in an effective amount that will not cause any substantial ablation of the bone ma ⁇ ow of said patient.
• Another aspect of the present invention provides for the use of a tubulin interacting compound for the preparation of a pharmaceutical composition for the treatment of cancer diseases and/or for the palliation of pain associated with cancer diseases, comprising the administration of the tubulin interacting compound in combination with a bone-localising radiopharmaceutical to the patient in an effective amount that will not cause any substantial ablation of the bone ma ⁇ ow of said patient.
• said tubulin interacting compound is administered before and/or after the administration of the bone-localising radiopharmaceutical.
• said effective amount is effective for bone pain relief in said patient.
• said cancerous disease is selected from the group of cancer diseases, comprising multiple myeloma, leukaemia, lymphoma, breast cancer, prostate cancer, gynecologic cancer, gastric cancer ovarian cancer, lung cancer and/or renal cell carcinoma.
• cancer diseases comprising multiple myeloma, leukaemia, lymphoma, breast cancer, prostate cancer, gynecologic cancer, gastric cancer ovarian cancer, lung cancer and/or renal cell carcinoma.
• said cancerous disease is a cancer with bone metastasis, such as metastatic breast cancer or metastatic prostate cancer.
• said cancerous disease is hormone-refractory prostate cancer (HRPC).
• said bone-localising radiopharmaceutical is selected from the group consisting of the radionuclides 177 Lu, 175 Yb, 186 Re, 188 Re, 90 Y, " 7 mSn, 153 Sm, 166 Ho or 159 Gd that are complexed with a bone-localising chelating agent selected from the group consisting of polyaminocarboxylic acids and aminophosphonic acids, in particular samarium Sm 153 lexidronam, and Sr-chloride.
• Prefe ⁇ ed are aminophosphonic acids that are selected from the group consisting of EDTMP, DOTMP, DTPMP, HEEDTMP, NTMP, HEDP, HMDP, MDP, and TTHMP, and combinations thereof, and polyaminocarboxylic acids that are selected from the group consisting of DTP A, EDTA, and DOTA, and combinations thereof.
• said bone-localising radiopharmaceutical is administered at a dose of between about 0.005 to 5.0 mCi/kg, and preferably administered at a dose of 1.0 mCi/kg.
• the amount of the tubulin interacting compound that is used is administered at a dose of between 20 to 100 mg/m /week, and pref- erably administered at a dose of approximately between 30 to 70 mg/m /week.
• said tubulin interacting compound is interacting directly and/or indirectly and is a chemotherapeutic agent selected from the group comprising vinca alkaloids, such as vincristine, vinblastine, vindesine, vinorelbine, taxanes, such as paclitaxel, docetaxel, epothilone A or B, and the like.
• the che- motherapeutic agent is Taxol and is administered in a dose of approx. 70 mg/m /week or is Taxotere which is administered in a dose of approx. 25-40 mg/m /week.
• Yet another prefe ⁇ ed use according to present invention comprises the administration of said bone-localising radiopharmaceutical is performed in a time period ranging from about 1 to 30 days, and preferably 1 to 7 days, before and/or after the administration of said tubulin interacting compound.
• the bone-localising radiopharmaceutical is administered in at least 8 week-intervals, preferably 16 week-intervals, during the course of a weekly administration of said tubulin interacting compound.
• Prefe ⁇ ed is a use according to the present invention, further comprising the administration of estramustine phosphate sodium, which is preferably administered weekly at a dose of between approximately 100 to 400mg, more preferably at approximately 280 mg twice a day.
• said administration is intravenous (i.v.), orally (p.o.), and/or subcutaneously.
• said administration is in a bolus dose or in several doses.
• kits of parts for the treatment of a cancer disease and/or for the palliation of pain associated with cancer diseases comprising the following components: a) a pharmaceutically effective amount of a bone-localising radiopharmaceutical, b) a pharmaceutically effective amount of a tubulin interacting compound, and c) optionally, suitable pharmaceutically acceptable buffers and/or diluents, wherein the amount of the bone-localising radiopharmaceutical comprises an effective amount of said bone-localising radiopharmaceutical that will not cause any substantial ablation of the bone ma ⁇ ow when applied to a patient.
• kits according to the present invention wherein said bone-localising radiophar-
• 77 1 1 Rft maceutical is selected from the group consisting of the radionuclides Lu, Yb, Re, 188 Re, 90 Y, 117 mSn, 153 Sm, 166 Ho or I59 Gd that are complexed with a bone-localising chelating agent selected from the group consisting of polyaminocarboxylic acids and aminophosphonic on acids, in particular samarium Sm 153 lexidronam, and Sr-chloride.
• said aminophosphonic acids are selected from the group consisting of EDTMP, DOTMP, DTPMP, HEEDTMP, NTMP, HEDP, HMDP, MDP, and TTHMP, and combinations thereof, and wherein said polyaminocarboxylic acids are selected from the group consisting DTP A, EDTA, and DOT A, and combinations thereof.
• said bone- localising radiopharmaceutical is suitable for the administration at a dose of between about 0.005 to 5.0 mCi/kg, preferably at a dose of 1.0 mCi/kg.
• said tubulin interacting compound is suitable for the administration at a dose of between 20 to 100 mg/m /week, and preferably administered at a dose of approxi- mately between 30 to 70 mg/m /week.
• the tubulin interacting compound is suitable for administration before or after the administration of said bone-localising radiopharmaceutical.
• the tubulin interacting compound is a chemotherapeutic agent selected from the group comprising vinca alkaloids, such as vincristine, vinblastine, vindesine, vinorelbine, taxanes, such as paclitaxel, docetaxel, epothilone A or B, and the like.
• the chemotherapeutic agent is Taxol and is suitable for administration in a dose of approx. 70 mg/m /week or is Taxotere which is suitable for administration in a dose of approx. 25-40 mg/m 2 /week.
• said bone-localising radiopharmaceutical is suitable for administration in a time period ranging from about 1 to 30 days, and preferably 1 to 7 days, before and/or after the administration of said tubulin interacting compound.
• said bone- localising radiopharmaceutical is suitable for administration in at least 8 week-intervals, pref- erably 16 week-intervals, during the course of a weekly administration of said tubulin interacting compound.
• the present invention in one aspect features the use of a kit, wherein said cancerous disease is selected from the group of cancer diseases, comprising multiple myeloma, leukaemia, lymphoma, breast cancer, ovarian cancer, lung cancer, renal cell carcinoma, and/or for bone pain relief in said patient.
• a preferred use of a kit according to the invention is in the treatment of hormone-refractory prostate cancer (HRPC) and/or is a cancer with bone metastasis, such as metastatic breast cancer or metastatic prostate cancer.
• said administration is intravenous (i.v.), orally (p.o.), and/or subcutaneously.
• said administration is in a bolus dose or in several doses.
• Tubulin interacting compound shall mean a chemotherapeutic agent that directly (e.g. by interacting with the tubulin stem) and/or indirectly (e.g. by interaction with the microtubular associated proteins (MAP) or interference with the genetic expression of parts of the microtubular machinery of the cell) interferes with the tubulin-system of the cell(s) in order to disturb said system directly and/or indirectly, such as an inhibitor of cell division acting on tubulin.
• MAP microtubular associated proteins
• Treatment shall mean a process of the reversing or ameliorating or reducing a condition of a certain type or certain types of cells or tissues with respect to an abnormal behaviour, such as a proliferative disease.
• a treatment is applied to a patient.
• the treatment according to the present invention is performed in "treatment cycles" which shall mean either 8-week or 16- week time periods.
• a “bone-localising radiopharmaceutical” shall mean a radiopharmaceutical that is specifically used for the therapy and/or pain palliation of diseases related with bone-pain and/or bone- disease.
• diseases are either directly located in the bone itself (e.g. cancers of the bone ma ⁇ ow) or indirectly related to bone, such as bone-metastatic cancerous diseases, comprising multiple myeloma, leukaemia, lymphoma, breast cancer, ovarian cancer, prostate cancer, lung cancer, gynecologic cancer, gastric cancer and renal cell carcinoma, in particular hormone- refractory prostate cancer (HRPC).
• HRPC hormone- refractory prostate cancer
• “combination with” shall mean the administration of the tubulin interacting compound and/or the radiopharmaceutical and/or a chemotherapeutic agent according to the present invention to the patient in need thereof in a manner that allows for a synergistic therapeutical effect (radiosynergy) of said combination.
• the combination can be either concomitantly or spaced apart in time.
• the radiopharmaceutical is administered at week 1 of the treatment cycle, in combination with the tubulin interacting compound, and, optionally, with the chemotherapeutic agent. Nevertheless, any combination within a treatment cycle will be regarded as in "combination with” each other.
• “Pharmaceutical composition” shall mean a composition comprising at least one active ingredient, whereby the composition is amenable to investigation for a specified, efficacious outcome in a mammal (for example, and not as a limitation, a human).
• a mammal for example, and not as a limitation, a human.
• Those of ordinary skill in the art will understand and appreciate the techniques appropriate for determining whether an active ingredient has a desired efficacious outcome based upon the needs of the artisan, in this case the treatment of bone-associated diseases, such as cancer.
• the study will assess the efficacy of combination samarium Sm 153 lexidronam, (optionally estramustine), and docetaxel treatment in patients with HRPC.
• the design of samarium Sm 153 lexidronam combined with weekly administration of 30 mg/m /week docetaxel and, optionally, 560 mg/day estramustine administered 3 days/week will be chosen because it is expected to allow closer monitoring of safety and efficacy and is expected to have a lower overall toxicity profile compared to the regimen of docetaxel administered once every 3 weeks plus estramustine administered 5 days a week. Control groups will not be used in the present study.
• serum testosterone must be ⁇ 50 ng/mL with continuation of gonadotropin-releasing hormone agonist.
• Patients are excluded from the study if they meet any of the following criteria: Prior chemotherapy; Prior treatment with a systemic radiotherapeutic bone agent; Receipt of any other investigational drugs within 4 weeks of study entry; Receipt of palliative radiotherapy for bone metastases within 90 days of study entry; Pathologic long-bone fractures (unless surgically stabilised), imminent pathologic long-bone fracture (cortical erosion on radiography > 50%), or spinal cord compression; Metastatic involvement of> 75% of ribs, vertebrae, and pelvic bones on bone scan; Known hypersensitivity to phosphonate compounds, drugs formulated with polysorbate 80, or dexamethasone; Known hypersensitivity to estradiol or nitrogen mustard; History of active thrombophlebitis or thromboembolic disorders; History of deep vein thrombosis or pulmonary embolus; Known NYHA class III-IV congestive heart failure; Clinically relevant change in angina within 6 months of study entry; Myocardial in- farction within 1 year of study entry
• Patients are permanently removed from the study if they experience any of the following: DLT as defined below; More than two dose modifications of docetaxel; Inadequate ANC and platelet count status or recovery (ANC > 1500/mm and platelet count ⁇ 75,000/mm ) after a delay in samarium Sm 153 lexidronam treatment of up to 2 weeks; Grade 2 anaphylaxis or hypersensitivity if there is a recurrence after rechallenge with docetaxel treatment; Symptomatic a ⁇ hythmia; Symptomatic pleural effusion; Need for haematopoietic growth factor support; Disease progression; Receipt of antineoplastic therapy other than designated study treatment.
• DLT as defined below
• More than two dose modifications of docetaxel Inadequate ANC and platelet count status or recovery (ANC > 1500/mm and platelet count ⁇ 75,000/mm ) after a delay in samarium Sm 153 lexidronam treatment of up to 2
• Treatment will be administered on an outpatient basis in the clinical setting. No investiga- tional or commercial agents or therapies other than those described in this protocol are administered with the intent to treat the disease with the exception of continued use of gonado- tropin-releasing hormone agonist or bisphosphonates. Patients receiving bisphosphonate therapy will bisphosphonates withheld starting 2 weeks before and 2 weeks after each dose of samarium Sm 153 lexidronam. All patients undergo baseline visits and drug infusion in accordance with package insert guidelines. Clinical and laboratory monitoring will be performed in accordance with package insert guidelines.
• Samarium Sm 153 lexidronam used will be manufactured for Berlex Laboratories (Richmond, CA) by DuPont Pharmaceuticals Co. (Billerica, MA) under license from Cytogen Corp. (Princeton, NJ).
• Quadramet® is supplied frozen in a single-dose 10 mL glass vial containing 1850 ⁇ 185 MBq/mL (50 ⁇ 5 mCi/mL) of samarium- 153, at calibration. The vial is shipped in a lead shield. The drug product expires 48 hours after the time of calibration noted on the label, or 8 hours after thawing, whichever is earlier.
• Quadramet® In accordance with package insert requirements, Quadramet® must be stored frozen at - 10° to -20°C in a lead shielded container. Storage and disposal of Quadramet® should be controlled in a manner that complies with the appropriate regulations of the government agency authorised to license the use of this radionu- clide.
• Estramustine Phosphate Sodium (Emcyt® (estramustine)) is manufactured for Pharmacia & Upjohn Company (Kalamazoo, MI) by Pharmacia & Upjohn S.p.A. (Ascoli Piceno, Italy).
• Emcyt® is supplied as white opaque capsules, each containing estramustine phosphate sodium as the disodium salt monohydrate equivalent to 140 mg estramustine phosphate.
• Emcyt® capsules should be stored between 2°C and 8°C (36°F to 46°F).
• Taxotere® (docetaxel) is manufactured by Aventis Pharmaceuticals Products Inc. (Bridgewater, NJ). Taxotere® is supplied in a single-dose vial as a sterile, pyrogen-free, non- aqueous, viscous solution with an accompanying sterile, nonpyrogenic, diluent (13% ethanol in Water for Injection) vial.
• Taxotere® should be stored between 2°C and 25°C (36°F and 77°F). Retain in the original package to protect from bright light. Freezing does not adversely affect the product. Procedures for proper handling and disposal of antican- cer drugs should be considered.
• Response rates are estimated using the observed proportion of responders of those considered evaluable for response.
• CIs upper one-sided confidence intervals
• a patient's survival time will be defined as the time between enrollment into the study and last date of contact whether or not death occu ⁇ ed with censoring of data as necessary.
• the survival distribution of the time to death will be estimated using the product-limit method of Kaplan and Meier.
• Endpoints for this study are analysed descriptively based on summary statistics (mean, median, frequency, etc.). Primary and secondary endpoints will be calculated and described. The 2-sided chi-square test will be the only statistical testing performed. Patients are enrolled over a period of up to 12 months (including follow-up).
• a total of approx. 60 patients will be enrolled in the study, with each site enrolling 1 to 20 patients. It is anticipated that this number results in approx. 50 evaluable patients who will have completed two cycles of treatment.
• An initial cohort of approx. 10 patients will receive combination treatment. If two patients in the cohort exhibit a DLT, another four patients are treated at that dose with no more than two experiencing a DLT before Part 2 of the study will be initiated. The study will be permanently stopped if five or more of the initial 10 patients experience a DLT. Patients who do not experience a DLT in Part 1 can continue on to Part 2.
• DLT dose-limiting toxicity
• Secondary endpoints are, survival, response rate (as measured by prostate-specific antigen [PSA], computerised tomography [CT] scan or magnetic resonance imaging [MRI], or bone scan), and disease progression (as measured by PSA, CT scan or MRI, or bone scan).
• PSA prostate-specific antigen
• CT computerised tomography
• MRI magnetic resonance imaging
• bone scan as measured by PSA, CT scan or MRI, or bone scan.
• the primary objective will be to establish the safety and tolerability based on the incidence and severity of adverse events associated with samarium Sm 153 lexidronam administered in combination with optional estramustine and docetaxel.
• Estramustine will be optionally administered on Days 1-3 of Weeks 1-3 and 5-7 and will be given at a dose of 280 mg twice a day PO.
• Docetaxel will be administered at 30 mg/m /week on Day 1 of Weeks 1-3 and 5-7 of the 8-week cycle.
• Cycles 1 and 3 consist of combination samarium Sm 153 lexidronam/opt. estramustine/docetaxel therapy
• Cycles 2 and 4 consist of combination estramustine/docetaxel therapy.
• Patients must meet eligibility criteria prior to starting an additional cycle. Patients are permanently discontinued from the study if they experience disease progression. Study stopping rules are outlined above.
• Total duration of the study for each patient will be up to 36 weeks. This consists of four 8- week cycles of treatment (32 weeks total) and a follow-up evaluation 4 weeks after completion of the final cycle. Additional follow-up evaluations for survival status continue for up to 12 months after completion of the final cycle.
• Secondary objectives are to evaluate the efficacy of the combination regimen(s), including its impact on survival, response rate, disease progression, and pain.
• Samarium Sm 153 lexidronam will be administered through an established i.v. line over a period of 1 minute once every two 8-week treatment cycles (i.e., 16 weeks). Each patient receives up to two doses of samarium Sm 153 lexidronam if tolerated.
• Samarium Sm 153 lexidronam is sent frozen directly to the study site.
• Samarium Sm 153 lexidronam must be stored frozen in a shielded container until administration.
• the investigator assays samarium Sm 153 lexidronam for total radioactivity using a radioisotope dose calibrator with the proper calibration setting for samarium Sm 153 lexidronam.
• the total activity administered to each patient will be determined by assaying the syringe containing the dose both prior to and immediately following administration of samarium Sm 153 lexidronam.
• An aliquot of samarium Sm 153 lexidronam will be assayed to ensure the pH is in the range of 7.0-8.5.
• Samarium Sm 153 lexidronam is contraindicated in patients who have known hypersensitivity to EDTMP or similar phosphonic acid chelators. If signs of acute toxicity occur during the administration of samarium Sm 153 lexidronam, the infusion should be stopped and appropriate supportive measures should be taken.
• Estramustine will be administered on Days 1-3 of Weeks 1-3 and 5-7 of each 8-week cycle and will be given at a dose of 280 mg twice a day p.o..
• Warfarin will be administered at a dose of 2 mg/day p.o. every day for the duration of the study and will be started on the same day as estramustine administration.
• Docetaxel will be administered i.v. at a dose of 30 mg/m /week on Day 1 of Weeks 1-3 and 5- 7 of each 8-week cycle. Each patient receives up to a total of four cycles of docetaxel.
• Dexamethasone will be administered at a dose of 8 mg p.o. 12 hours prior to docetaxel dose, 1 hour prior to docetaxel dose, and 12 hours after docetaxel dose.
• estramustine and docetaxel for this study will be selected based on recent studies of weekly low-dose docetaxel plus shorter courses of estramustine that demonstrated similar efficacy with less toxicity in the HRPC setting compared to less frequent, higher dose do- cetaxel/estramustine therapy (Natale 1998, Natale 1999, Kosty 2000, Copur 2001). In addition, these agents have also demonstrated radiosensitising properties (Pradier 2001, Koukourakis 1998, Koukourakis 1999, Ekiov 1994, Ryu 1994, Edgren 2000, Kirn 1994).
• the FDA-approved dose of 1.0 mCi/kg samarium Sm 153 lexidronam will be selected to be given once every 16 weeks as this interval has been shown to allow for complete recovery of cell counts as well as provide maximum duration of pain relief (Serafini 2001).
• Patients will receive 1.0 mCi/kg samarium Sm 153 lexidronam on Day 2 of the 8-week cycle (dosing will be permitted between Days 1 and 3 to allow for possible drug shipment/scheduling conflicts).
• Estramustine will be optionally administered on Days 1-3 of Weeks 1-3 and 5-7 and will be given at a dose of 280 mg twice a day p.o..
• Docetaxel will be administered at 30 mg/m /week on Day 1 of Weeks 1-3 and 5-7 of the 8-week cycle.
• estramustine as well as prophylactic dexamethasone and warfarin
• patients will be instructed to administer estramustine (as well as prophylactic dexamethasone and warfarin) at the same times each day and to record the date and time of each administration in the patient diary in addition to analgesic use, other concomitant medications, pain, and adverse events.
• DLT will be defined as any of the following: Grade 4 neutropenia (ANC ⁇ 500/mm 3 ) with fever > 38.3°C; Grade 4 thrombocytopenia (platelet count ⁇ 10,000/mm 3 ); Any nonhaema- tologic Grade 3 or 4 toxicity with the exception of nausea, vomiting, mucositis, fatigue, or alopecia, or Grade 3 dia ⁇ hoea using NCI CTC criteria (Version 2.0, April 30, 1999). Disease progression or lack of disease response are not be considered DLT events.
• Grade 4 neutropenia ANC ⁇ 500/mm 3
• Grade 4 thrombocytopenia platelet count ⁇ 10,000/mm 3
• Any nonhaema- tologic Grade 3 or 4 toxicity with the exception of nausea, vomiting, mucositis, fatigue, or alopecia, or Grade 3 dia ⁇ hoea using NCI CTC criteria (Version 2.0, April 30, 1999). Disease progression or lack of disease response are not be considered DLT events.
• a patient experiences toxicity not meeting the definition for DLT the following criteria will be used to delay or modify samarium Sm 153 lexidronam, estramustine, and docetaxel dosing or to permanently discontinue a patient from the study.
• samarium Sm 153 lexidronam treatment Day 2 of Cycle 3
• patients must have ANC > 1500/mm 3 , platelet count > 75,000/mm 3 , and satisfactory recovery from non-haematological toxicity. If these criteria are not met on the scheduled day of treatment, the treatment must be delayed for up to 2 weeks. If ANC and platelet count do not recover within 2 weeks, the patient will be discontinued from the study.
• the patient's clinical and haematological responses to the initial dose of samarium Sm 153 lexidronam are taken into consideration prior to repeat treatment with samarium Sm 153 lexidronam.
• Bilirubin or SGOT/SGPT > 1.5 ULN If hepatic toxicity occu ⁇ ed (bilirubin or SGOT/SGPT > 1.5 ULN), estramustine is reduced or the patient is permanently discontinued from the trial at the discretion of the treating physician. Bilirubin and SGOT/SGPT values are obtained prior to each cycle of therapy and reviewed by the treating physician.
• ANC is ⁇ 1500/mm prior to beginning a cycle of treatment
• treatment will be delayed until ANC is > 1500/mm .
• Docetaxel will be resumed at 100%) dose unless the delay is > 7 days, in which case, decrease the subsequent docetaxel dose by 25%>.
• ANC does not recover within 2 weeks of delay in therapy
• the patient will be discontinued from the study.
• platelet count is ⁇ 75,000/mm 3 on the day of therapy, treatment will be delayed until > 75,000/mm 3 and subsequent doses of docetaxel will be permanently reduced by 25%. If the platelet count does not recover within 2 weeks of delay in therapy, the patient will be discontinued from the study.
• docetaxel will be reduced by 25%. If the bleeding episode does not re- solve with platelet count > 75,000/mm within 2 weeks of delay in therapy, the patient will be discontinued from the study.
• Docetaxel Nonhaematological Toxicity If a patient experiences nonhaematological toxicity, the following dose modification criteria are used: Patients who experience Grade 3 or 4 fatigue will have treatment withheld until they attain ⁇ Grade 2 recovery. Subsequent docetaxel doses are reduced by 25%.
• Loop diuretics should be used judiciously to treat fluid retention; Patients are discontinued from the study only if they experience symptomatic pleural effusion; Peripheral Neuropathy: If Grade 1 intensity, continued therapy at the full dose; If Grade 2 intensity, reduce docetaxel by 25%; Up to two dose reductions in docetaxel therapy are permitted for peripheral neuropathy. If a patient required further dose reduction due to neuropathy, study treatment will be discontinued. Hepatic: If hepatic toxicity occurs (bilirubin or SGOT/SGPT > 1.5 ULN), docetaxel will be reduced or the patient will be permanently discontinued from the trial at the discretion of the treating physician. Bilirubin and SGOT/SGPT values are obtained prior to each cycle of therapy and reviewed by the treating physician.
• Patients receiving LH-RH agonists continue the primary androgen ablation. Patients continue on medications for symptom relief (e.g., analgesics, hypnotics, anxiolytics) or an as-needed basis. Patients requiring other antineoplastic therapy following administration of study treatment will be removed from the trial.
• symptom relief e.g., analgesics, hypnotics, anxiolytics
• patients requiring other antineoplastic therapy following administration of study treatment will be removed from the trial.
• Haematopoietic growth factor support will not allowed be while patients are enrolled on the study. The use of erythropoietin will be at the discretion of the treating physician. Patients requiring growth factor support will be discontinued from the study but will be followed for safety. All medications administered during the study shall be reported on the CRFs and in the source documents.
• Patients will be supplied a diary in which to record the date and time of each estramustine, dexamethasone, and warfarin dose in addition to analgesic use, other concomitant medications, pain, and adverse events.
• Study site staff reviews the diary with the patient at each scheduled clinic visit and transcribes all pertinent information onto the CRF. The diaries are retained at the study site as part of the source documentation.
• Procedures for safety and efficacy measurements and flow chart The investigative team at each study site will be responsible for performing all evaluations and recording information on source documents as well as completing CRFs. When possible, the same staff personnel performs all evaluations for a given patient. All laboratory analyses are performed by local laboratories except for serum PSA analyses, which are performed at a central laboratory.
• the treatment room will be surveyed by the Radiation Safety Officer. Patients may be discharged from the test facility when the exposure reading complies with state and federal regulations.
• Patients will have the following procedures completed at the end of the study: Patient diary review; VAS; Adverse event assessment; Physical examination, including weight; Vital signs; CBC; Serum chemistry (creatinine, BUN, total bilirubin, alkaline phos- phatase, SGOT, SGPT, sodium, potassium, chloride, bicarbonate, glucose, albumin, total protein, calcium, phosphorus); Serum PSA (analysed at a central laboratory); Coagulation profile (PT/PTT); Urinalysis; Karnofsky performance status; 99Tc bone scan; CT scan or MRI for patients with measurable disease.
• Prostate-Specific Antigen Working Group (PSAWG) disease assessment criteria (Bubley 1999), VAS (Akhar-Danesh 2001), and Karnofsky performance status are standard accepted tools of measurement in HRPC.
• Combination therapy with RED will be quite effective, particularly when evaluated in the context of a multiinstitutional trial (BrUOG: five hospitals with varied patient populations including private, indigent, veterans hospitals), but maybe it will be difficult to estimate the contribution from the individual agents.
• Estramustine potentiates the radiation effect in human prostate tumor transplant in nude mice. Prostate 1994;24(l):39-45.
• Hudes G Estramustine-based chemotherapy. Semin Urol Oncol 1997a; 15(1): 13-9. Hudes GR, Nathan F, Khater C, et al. Phase II trial of96-hour paclitaxel plus oral estramustine phosphate in metastatic hormone-refractory prostate cancer. J Clin Oncol 1997b; 15(9):3156- 63.
• Petrylak DP Macarthur R, O'Connor J, et al. Phase I/II studies of docetaxel (Taxotere) combined with estramustine in men with hormone-refractory prostate cancer. Semin Oncol 1999;26(5 Suppl 17):28-33.

Landscapes

• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Public Health (AREA)
• Veterinary Medicine (AREA)
• Medicinal Chemistry (AREA)
• General Health & Medical Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• Pharmacology & Pharmacy (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Organic Chemistry (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• General Chemical & Material Sciences (AREA)
• Epidemiology (AREA)
• Proteomics, Peptides & Aminoacids (AREA)
• Oncology (AREA)
• Optics & Photonics (AREA)
• Physics & Mathematics (AREA)
• Hematology (AREA)
• Biomedical Technology (AREA)
• Neurology (AREA)
• Neurosurgery (AREA)
• Biochemistry (AREA)
• Biophysics (AREA)
• Molecular Biology (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Engineering & Computer Science (AREA)
• Pain & Pain Management (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Priority Applications (1)

Applications Claiming Priority (4)

Publications (1)

Family

ID=32991002

Family Applications (2)

Family Applications Before (1)

Country Status (3)

Families Citing this family (4)

Family Cites Families (4)

• 2003
  • 2003-05-23 EP EP03011721A patent/EP1475105A1/de not_active Withdrawn
• 2004
  • 2004-04-27 WO PCT/EP2004/004434 patent/WO2004098651A2/en not_active Ceased
  • 2004-04-27 JP JP2006505288A patent/JP2006525965A/ja active Pending
  • 2004-04-27 EP EP04739109A patent/EP1622650A2/de not_active Withdrawn

Non-Patent Citations (1)

Also Published As

Similar Documents

Legal Events